pharmaphorum

JULY 8, 2022

The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the clinical trial space. Hybrid or decentralised clinical trials (DCTs) have gained traction as technology, infrastructure and knowledge have evolved to support their use. New sensor technology revolutionising data collection.

Drug Development 100

Drug Development Diabetes 100

European Pharmaceutical Review

JULY 15, 2022

In a report supported by the AMR Industry Alliance , One Health Trust described the current climate for antimicrobial innovation, focusing on regulatory challenges and opportunities for the approval of new antibiotics in Brazil, India, and South Africa.

88

88

pharmaphorum

DECEMBER 14, 2020

Armed with new data from a randomised clinical trial, one company is hoping to change that mindset. D aimed at people living with diabetes, which is undergoing clinical testing in the US and India. Bhargav Sri Prakash. Meanwhile, its turning its attention to other apps, notably fooya!D

Diabetes 111

Diabetes Communication Immunity Immunization 111

pharmaphorum

JULY 4, 2022

Hughes – currently Vertex’s head of clinical development and translational medicine – will make the move to his new employer on 1 August, less than a year after taking on the role. Eric A Hughes. He will be based out of Teva’s US headquarters in Parsippany, New Jersey.

Generic Medicine 52

Generic Medicine Biosimilars 52

pharmaphorum

OCTOBER 26, 2022

mjn-SERAS already has a CE mark in Europe and is currently in clinical testing, with results due in 2023. Bringing Neuraxpharm onboard provides an opportunity for mjn-neuro to accelerate the take-up of the wearable device, piggybacking on the 37-year-old drugmaker’s sales channels across Europe.

Communication 64

Communication 64

pharmaphorum

AUGUST 3, 2021

The FDA has relaxed a clinical hold on clinical trials of Novartis’ intrathecal formulation of spinal muscular atrophy (SMA) gene therapy Zolgensma, allowing a new phase 3 trial to get underway. They will fall into the category of SMA type 2, a less severe form of the disease.

105

105

Board Vitals - Pharmacist

APRIL 7, 2022

If you’re like most nursing students, your clinical experiences will be either the best or worse (or potentially both) part of nursing school. There are many factors that influence the quality of your clinical experience. Your experience in nursing clinicals hinges heavily on your assigned preceptor (the RN that you will be shadowing).

Hospitals 52

Hospitals 52

pharmaphorum

MARCH 29, 2021

Her experience spans many categories including oncology & immunology, rare disease, respiratory, women’s health, diabetes, nutrition and hospitals. Throughout her career she has worked with industry leaders including AstraZeneca, Pfizer, Lilly, Sanofi, GSK, Johnson & Johnson, Janssen, Merck, Genentech, and the Mayo Clinic.

Mayo Clinic 69

Mayo Clinic Diabetes Pharmaceutical Companies Pharmaceutical Companies 69

pharmaphorum

NOVEMBER 16, 2021

This could form a new commitment in the successor to the voluntary scheme learning from experience from measuring uptake on five highest health gain categories of medicines. For example, it was not defined upfront what the five HHG categories would be and how they would be chosen. That timetable translated to June 2021.

Dosage 96

Dosage 96

pharmaphorum

AUGUST 31, 2022

It is actually the control formulation used in clinical development of its original product MED2005, which contained glyceryl trinitrate as an active ingredient. However, “the USA remains the largest market opportunity globally for ED treatments,” said Futura’s chief executive, James Barder.

52

52

FDA Law Blog: Biosimilars

JUNE 22, 2023

Though there has been a large number of OTC IVD clearances and decades of experience reviewing OTC IVDs, the bulk of OTC IVD clearances fall in just a few categories, such as pregnancy tests, drugs of abuse tests, and glucose monitoring devices. In the intervening decades, FDA has cleared approximately 1,200 OTC IVDs. lay users).

Labelling 59

Labelling Hospitals 59

Drug Channels

JANUARY 19, 2021

With Expert Keynotes, In-Depth Workshops and Live Q&A Opportunities and other virtual features, you’ll end your week ready to advance your organization to stay ahead in 2021. Cannot be combined with special category rate or non-profit rates. Cannot be combined with other offers or used towards a current registration.

52

52

pharmaphorum

NOVEMBER 10, 2021

It is competing in the US with rival oral CGRPs, namely AbbVie’s Qulipta (atogepant) which was approved for episodic migraine prevention in September and AbbVie’s Ubrelvy (ubrogepant) in the acute treatment category, as well as several CGRP-targeting antibodies delivered by injection or infusion from Amgen, Eli Lilly, Teva and Lundbeck.

52

52

pharmaphorum

NOVEMBER 3, 2022

The studies involved more than 3,000 female adults and adolescents with uncompleted UTIs and showed that a five-day oral course of gepotidacin was as effective as standard therapy nitrofurantoin at achieving combined clinical and microbiological responses to the infection at 28 days.

98

98

pharmaphorum

APRIL 11, 2022

Dudley Tabakin, CEO of VivoSense, describes how this financing is set to accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments. How can this data be incorporated into clinical trials?”. We believe that VivoSense is ‘the tip of the spear’ in this category.”. Tabakin agrees. “In

Pharmaceutical Companies 111

Pharmaceutical Companies Pharmaceutical Companies Drug Development Packaging 111

Putting Patients First Blog

MAY 22, 2023

We encourage CMS to consider what evidence may be needed for each identified category and support the broadest scope of evidence that may be considered. The goal of this information should be to demonstrate how patient benefits and clinical appropriateness influenced the final decision.

Drug Pricing 40

Drug Pricing Drug Development 40

pharmaphorum

NOVEMBER 2, 2022

Australia’s CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other respiratory pathogens, including those that may cause future pandemics.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

MARCH 31, 2022

UK startup Sano Genetics has raised $11 million in first-round financing to develop its go-between service, which aims to overcome one of the big challenges in clinical research by connecting patients with trial sponsors. There’s no cost to participants, but study sponsors pay a subscription fee to access the patient database.

Drug Development 52

Drug Development 52

pharmaphorum

AUGUST 2, 2021

UCB is bringing up the rear of the IL-17 inhibitor category with bimekizumab, which will be a latecomer if approved behind drugs like Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Bausch Health’s Siliq/Kyntheum (brodalumab).

52

52

FDA Law Blog: Biosimilars

JULY 24, 2023

This time, rather than use codes and patent certifications, the fight is over orphan drug exclusivity (“ODE”), with Jazz challenging FDA’s clinical superiority decision concerning sodium oxybate in the treatment of narcolepsy. 360cc(c), the statute does not permit FDA to promulgate regulations to use clinical superiority to break ODE.

52

52

pharmaphorum

AUGUST 25, 2021

The drugmaker has looked close to home for its latest entry into the category, as Lycia’s founder Prof Carolyn Bertozzi has held a seat on its board of directors since 2017 – a position she has now surrendered as a result of the deal. Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6

69

69

pharmaphorum

MARCH 22, 2022

A review of clinical studies published in 2015 found response rates of between 24% and 73% with the technique. GDH is designed to influence pain sensation and promote healthier control of digestive tract function by addressing a “miscommunication” between the brain and gut. metaMe’s latest fundraising added to $3.8

59

59

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category. Mar 1;23(5):2736.

Immunity 106

Immunity Immunization Vaccines Hospitals 106

pharmaphorum

OCTOBER 7, 2022

When it comes to the horizontal plays, Debong sees two big categories. The other broad category is around data exchange. Because data is still not interoperable, there are a lot of great opportunities for companies to build services around easy data exchange. One is around payment and reimbursement. Making connections.

Documentation 98

Documentation Diabetes 98

pharmaphorum

SEPTEMBER 30, 2021

Data showing that Prevnar 20 can be administered alongside the flu jab could provide more convenience for patients, who would be able to book in for both shots at the same time and avoid two clinic visits. “However, vaccination rates decline when someone needs to make multiple appointments to receive these vaccines,” he added.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

MARCH 22, 2022

million tied to clinical, regulatory, and commercial milestones as well as royalties on sales if MVA-BN RSV is launched in those markets. The agreement gives Bavarian Nordic a leg-up in the big Chinese market, as it tried to keep pace with heavyweight rivals in the RSV vaccine category closer to home. million, with another $212.5

Vaccines 52

Vaccines 52

Syner-G

SEPTEMBER 20, 2023

Drug repurposing, also known as drug repositioning paves an alternate path for drug development which involves identifying new therapeutic indications or uses for the existing molecules that could have been initially approved for or have clinically failed in a different indication.

Drug Development 59

Drug Development Documentation Dosage Packaging 59

pharmaphorum

JUNE 25, 2021

Disruption creates opportunity, and what happens with that opportunity is up to us to shape. After COVID, there is an opportunity to reset the playing field for CVD.”. Notably, he says, the world now has a much greater understanding of how access to care has become a major issue. Think about that. That to me is shocking.”.

Communication 100

Communication Drug Development 100

PharmaState Academy

FEBRUARY 29, 2024

CASE STUDY Seizing Opportunities Launching a Revolutionary Pharmaceutical Product Across Diverse Tier 2 Cities Table of Contents Case Study Introduction: Introduction to the case study focusing on launching a new pharmaceutical product in multiple Tier 2 cities in India.

Health and Personal Care Stores 52

Health and Personal Care Stores Hospitals Communication Customer Service 52

pharmaphorum

DECEMBER 11, 2022

And although not all categories involve patients directly, Hadjiat says, they all need to start from a place of patient centricity and patient need. “As Hadjiat says the team can build digital tools for clinicians because they have a team that represents both technical and clinical expertise. Conclusion.

Hospitals 137

Hospitals 137

pharmaphorum

SEPTEMBER 22, 2020

The Swiss pharma giant is paying €380 million (around $450 million) upfront for Dublin-based Inflazome, getting rights to a portfolio of oral NLRP3-targeting drugs including two candidates at the clinical testing stage, and has also pledged undisclosed milestone payments.

Immunity 59

Immunity Immunization 59

pharmaphorum

JANUARY 26, 2021

There is an opportunity to address this at scale with digital tools and techniques, and expand support into just about any therapeutic area through the holistic integration of mental and behavioural health solutions that improve patient care. Clinical trials get more and more digitalised. Aging in place’ becomes more commonplace.

Health and Personal Care Stores 141

Health and Personal Care Stores Medication Guidelines Communication 141

Pharmaceutical Technology

OCTOBER 26, 2022

Experts at the recent webinar presented health equity data, showing the opportunities to achieve significant financial gain whilst reducing health inequity. These principles also aim to allow an acknowledgement of Black and brown mistrust of clinical trials. trillion in savings over the next decade.

Pharmaceutical Companies 64

Pharmaceutical Companies Pharmaceutical Companies Hospitals Drug Development 64

European Pharmaceutical Review

FEBRUARY 21, 2023

Arthur Wakeley What data can you share about clinical trials for cannabis-based medicines? Early results for pain reduction, sleep and opioid reduction from a live study at a London-based clinic assessing the efficacy of cannabis-based medicines for chronic pain have been hugely encouraging.

Pharmaceutical Companies 129

Pharmaceutical Companies Pharmaceutical Companies Compounding Drug Development 129

Drug Channels

NOVEMBER 2, 2020

Held in a 100% virtual format, this four-day meeting convenes diverse stakeholders to discuss opportunities for continued innovation, advancement of impactful patient advocacy and acceleration of commercial strategy success. Cannot be combined with special category rates, clinic/hospital rates, non-profit/advocacy rates or other offers.

Hospitals 52

Hospitals Drug Development 52

Drug Channels

SEPTEMBER 21, 2020

Executive Director , National Association of Specialty Pharmacy (NASP) David Kowalsky, Director, Market Access and Patient Services , EyePoint Pharmaceuticals Andrew Gettinger, Chief Clinical Officer , ONC at US Department of Health & Human Services And more! Arquette, R.Ph., REGISTER TODAY.

Specialty Pharmacies 52

Specialty Pharmacies 52

Pharmaceutical Technology

MARCH 22, 2023

Of the 37 in clinical trials and 24 in early development, GlobalData forecasts that 27 will receive regulatory approval by 2025. There are at least 22 mHealth apps in product pipelines designed for patients with substance use disorders that fill this latter category and will require regulatory approval.

52

52